Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Asso
Go back to Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Asso| (NASDAQ: CADL) | Delayed: 9.08 -0.07 (0.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.15 | 52 Week High | $ | |||
| Open | $8.96 | 52 Week Low | $ | |||
| Day High | $9.32 | P/E | N/A | |||
| Day Low | $8.96 | EPS | $ | |||
| Volume | 1,377,984 | |||||
